• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zymeworks Inc. - Common Stock (NQ:ZYME)

    18.11 +0.05 (+0.30%)
    Streaming Delayed Price Updated: 1:11 PM EDT, Oct 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Zymeworks Inc. - Common Stock

    < Previous 1 2 3 Next >
    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
    Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251. 
    Via Benzinga
    Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
    The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
    Via Stocktwits
    Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
    From Zymeworks Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 7, 2025
     
    Via Benzinga
    Earnings Scheduled For May 8, 2025
     
    Via Benzinga
    Deep Dive Into Zymeworks Stock: Analyst Perspectives (4 Ratings)
     
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
     
    Via Benzinga
    Which stocks are moving after the closing bell on Friday?
    Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
    Via Chartmill
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
    Company to participate in investor conferences in July and August 
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
    Zymeworks is entitled to receive a $20 million milestone payment in connection with the NMPA approval of zanidatamab as part of its agreement with BeOne Medicines. 
    Via Stocktwits
    Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
    The research firm expects key clinical data in late 2025 and sees Ziihera royalties funding pipeline development. 
    Via Stocktwits
    Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
    Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone adds $14M to cash reserves. 
    Via Benzinga
    Topics Earnings
    Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration
    From Zymeworks Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 5, 2025
     
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.